Cancer Genetics Announces 1-for-30 Reverse Stock Split
October 24, 2019 08:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it...
Precipio Conducts IV-Cell™ Validation Trial with a Prominent Laboratory
May 06, 2019 09:20 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 06, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary IV-Cell...
Cancer Genetics, Inc. is Among the First To Drive New FDA-Approved Testing Paradigm for Non-Small Cell Lung Cancer Patients by Offering Thermo Fisher Scientific’s Oncomine Dx Target Test
November 02, 2017 07:30 ET
|
Cancer Genetics, Inc.
Thermo Fisher’s multi-biomarker test helps match lung cancer patients to FDA-approved therapies in days instead of weeksCGI and Thermo Fisher are collaborating with pharmaceutical partners and...
Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
October 12, 2017 07:30 ET
|
Cancer Genetics, Inc.
Cancer Genetics Will Also Present a Corporate Overview on Thursday, October 19th RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a...
American Health Council Names Carlos Encarnacion, M.D. to Physician Board
December 14, 2016 11:36 ET
|
American Health Council
NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Dr. Carlos Encarnacion, Physician at Texas Oncology, has been selected to join the Physician Board at the American Health Council. He will be sharing...